The COLICA (Colchicina en Insuficiencia Cardiaca Aguda) trial focused specifically on acute heart failure and found that while colchicine effectively reduced inflammatory markers (CRP, IL-6), it failed to demonstrate significant improvements in heart failure clinical outcomes [82]. Here, CRP is linked to heart failure.